Table 4.

Adjusted OR and 95% CI for the associations between aspirin use, frequency, and duration and NSCLC risk in the NCI-Maryland NSCLC Case–Control Study, among only men

ModelaModelbModelc
Aspirin useOR (95% CI)POR (95% CI)POR (95% CI)P
 NoReferenceReferenceReference
 Yes0.61 (0.48–0.79)<0.00010.72 (0.55–0.93)0.010.66 (0.49–0.89)0.006
Daily aspirin use
 NeverReferenceReferenceReference
 <1 tablet per day0.37 (0.14–0.98)0.040.33 (0.12–0.90)0.030.40 (0.12–1.31)0.13
 ≥1 tablet per day0.63 (0.49–0.81)<0.00010.74 (0.57–0.96)0.030.68 (0.50–0.90)0.01
 Trend<0.00010.030.01
Duration of aspirin use
 NeverReferenceReferenceReference
 < 3 years0.77 (0.52–1.15)0.210.94 (0.62–1.42)0.770.93 (0.58–1.45)0.75
 ≥ 3 years0.55 (0.42–0.72)<0.00010.63 (0.47–0.85)0.0020.61 (0.44–0.85)0.003
Trend<0.00010.0020.003
  • aAdjusted for age, smoking, pack-years, education, family history of lung cancer, marital status, year of interview, use of Tylenol, and other NSAIDs.

  • bAdjusted for age, smoking, pack-years, education, family history of lung cancer, marital status, year of interview, use of Tylenol and other NSAIDs, and BMI at diagnosis.

  • cAdjusted for age, smoking, pack-years, education, family history of lung cancer, marital status, year of interview, use of Tylenol and other NSAIDs, BMI at diagnosis, and global genetic ancestry.

  • Bold values denote statistical significance.